Our patient's successful outcome can be attributed to relatively simple treatment for MCD: that is rituximab; and extensive multi-organ care support on the ICU. Rituximab is a newly-established therapy for MCD [1] . Its efficacy has thus far been chiefly demonstrated in limited studies of patients outside of the intensive care setting. Recent literature suggests ICU admission and support can be beneficial for haemato-oncological patients to facilitate specific chemotherapy [6] . Consistent with this notion, our report illustrates the benefit of ICU support during rituximab treatment for HIV associated MCD.